Press/Media
- 1 - 25 out of 198 results
Search results
-
Reports Outline Acute Myeloid Leukemia Study Findings from Northwell Health (Impact of Fluoroquinolone Prophylaxis On Neutropenic Fever, Infections, and Antimicrobial Resistance In Newly Diagnosed Aml Patients)
Erin Moshier, Nicole Zubizarreta, Guido Lancman, Douglas Tremblay & John Mascarenhas
23/03/23
1 item of Media coverage
Press/Media
-
Dr. Mascarenhas on the Role of Pacritinib in Myelofibrosis
8/03/23
1 item of Media coverage
Press/Media
-
Mascarenhas Summarizes Therapeutic Standards and Advances in Myelofibrosis Management
23/02/23
1 item of Media coverage
Press/Media
-
AML Research From ASH 2022: Novel Combinations and Evidence That “Less is More”
3/01/23 → 8/02/23
2 items of Media coverage
Press/Media
-
Dr. Mascarenhas on the Evolution of JAK Inhibitors in Myelofibrosis
7/02/23
1 item of Media coverage
Press/Media
-
Clinical Review of ropeginterferon alfa-2b Suggests Amended Dosing Schedule May Support Improved Clinical Outcomes in Polycythemia Vera
2/02/23
2 items of Media coverage
Press/Media
-
Study Findings on Acute Myeloid Leukemia Published by Researchers at Icahn School of Medicine at Mount Sinai (The Latest Breakthroughs in Immunotherapy for Acute Myeloid Leukemia, with a Special Focus on NKG2D Ligands)
Lucas Ferrari de Andrade & John Mascarenhas
9/01/23
1 item of Media coverage
Press/Media
-
Reports on Myelofibrosis from Icahn School of Medicine at Mount Sinai Provide New Insights (Biological Drivers of Clinical Phenotype In Myelofibrosis)
Ronald Hoffman & John Mascarenhas
26/12/22
1 item of Media coverage
Press/Media
-
Pelabresib-ruxolitinib combination reduces spleen volume, symptom score in myelofibrosis
21/12/22
1 item of Media coverage
Press/Media
-
MorphoSys Presents New Longer-term Phase 2 Results on Pelabresib in Myelofibrosis, Including Potential Disease-Modifying Activity, at ASH 2022
11/12/22 → 12/12/22
11 items of Media coverage
Press/Media
-
Mount Sinai Study Uncovers Inflammatory Markers that May Predict a Response in Certain Patients to COVID-19 Immunotherapies
5/12/22 → 7/12/22
2 items of Media coverage
Press/Media
-
Study Uncovers Inflammatory Markers that May Predict Response in Certain Patients to Covid Immunotherapies
6/12/22
1 item of Media coverage
Press/Media
-
Mount Sinai study uncovers inflammatory markers that may predict a response in certain patients to COVID-19 immunotherapies
5/12/22
4 items of Media coverage
Press/Media
-
Expanding Treatment Options Elevate Outcomes for Patients With Myelofibrosis
28/11/22
1 item of Media coverage
Press/Media
-
Dr. Mascarenhas on Advancements in the Treatment Landscape of Myelofibrosis
28/11/22
1 item of Media coverage
Press/Media
-
VIDEO: Reviewing uses of JAK2 inhibitors in myelofibrosis
16/11/22
1 item of Media coverage
Press/Media
-
VIDEO: Myeloproliferative neoplasms treatment may be ‘driven by genomic distinctions’
15/11/22
1 item of Media coverage
Press/Media
-
VIDEO: Understanding the ‘pivotal role’ NF-cappaB plays in myeloproliferative neoplasms
15/11/22
1 item of Media coverage
Press/Media
-
With Transplant the Only Cure for Myelofibrosis, Clinical Trials, Patient-Provider Communication Is Key
14/11/22
1 item of Media coverage
Press/Media
-
VIDEO: New treatments in myeloproliferative neoplasms signal ‘exciting’ time for field
11/11/22
1 item of Media coverage
Press/Media
-
Dr. Mascarenhas on the Potential Clinical Significance of Pacritinib in Myelofibrosis
18/10/22
1 item of Media coverage
Press/Media
-
Dr. Mascarenhas on the Effect of Pacritinib on Anemia in Myelofibrosis
7/10/22
1 item of Media coverage
Press/Media
-
Dr. Mascarenhas on the Investigation of Pelabresib in Myelofibrosis
23/09/22
1 item of Media coverage
Press/Media
-
Study Will Analyze Imetelstat-Jakafi Combination for Myelofibrosis
30/08/22
1 item of Media coverage
Press/Media
-
Geron Announces First Patient Dosed in IMproveMF Phase 1 Combination Study in Frontline Myelofibrosis
22/08/22 → 23/08/22
25 items of Media coverage
Press/Media